Last 12 months
Inside the activity.
7 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 9 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 2 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2026 Filed Jul 23, 2026 22:52 UTC |
Simon FarrellDirector
|
GrantStock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001965585-26-000006 · wk-form4_1784847165.xml · derivative · entry 1 Simon Farrell · CIK 0001965585 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2036-07-22 F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 16:05 UTC |
Brannan Stephen K.Director
|
PurchaseCommon Stock | 1,000 | $2.03 | $2,030.00 |
DisclosureSEC source: 0001777631-26-000007 · wk-form4_1783613110.xml · nonDerivative · entry 1 Brannan Stephen K. · CIK 0001777631 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:12 UTC |
Marshall Richard PeterDirector
|
GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0002016188-26-000004 · wk-form4_1782169969.xml · derivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:13 UTC |
Brannan Stephen K.Director
|
GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001777631-26-000005 · wk-form4_1782170028.xml · derivative · entry 1 Brannan Stephen K. · CIK 0001777631 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC |
Venkatesan JayDirector
|
ConversionSeries A Convertible Preferred Stock · Derivative | 96,525 | $2.25 Strike: $5.18 | $217,181.25 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · derivative · entry 4 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Jay Venkatesan Legacy Trust Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value · 222,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC |
Venkatesan JayDirector
|
GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · derivative · entry 3 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F3 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:15 UTC |
Venkatesan JayDirector
|
ConversionCommon Stock | 224,152 | $2.25 | $504,342.00 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · nonDerivative · entry 2 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Jay Venkatesan Legacy Trust Disclosed balance after: 231,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock. F1 · balance_after: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC |
Bailey GregoryDirector
|
ConversionSeries A Convertible Preferred Stock · Derivative | 762,548 | $2.25 Strike: $5.18 | $1,715,733.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.0001 par value · 1,755,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.expiration_date: The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC |
Bailey GregoryDirector
|
GrantRedeemable Warrants · Derivative | 3,333,333 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333,333 Underlying: Common Stock · 3,333,333 shares Expires 2030-03-17 F5 · shares: Issued pursuant to the same Securities Purchase Agreement dated March 17, 2026, covering 50% of the shares underlying the Pre-Funded Warrants acquired by the reporting person. The Company may call the warrants at $0.01 per underlying share upon 30 days' notice if the Common Stock closing price equals or exceeds $10.00 on the business day prior to the redemption notice, on the earlier of (i) 30 days after first patient dosing in Cohort 2 of the Company's SER-252 Phase 1b SAD study or (ii) September 30, 2026. Holders have 30 days to exercise following a call notice. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC |
Bailey GregoryDirector
|
GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · derivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F4 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC |
Bailey GregoryDirector
|
ConversionCommon Stock | 6,666,667 | $2.25 | $14,999,334.08 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,564,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Issued pursuant to a Securities Purchase Agreement dated March 17, 2026, at a purchase price of $2.2499 per pre-funded warrant (reflecting a $0.0001 exercise price). The Pre-Funded Warrants have no expiration date and are subject to customary beneficial ownership limitations. The exercise price and share count are subject to adjustment for stock splits, dividends, and similar events. Under NYSE American rules, issuance of the underlying shares to the reporting person is subject to prior stockholder approval which was obtained on June 17, 2026, thereby triggering the automatic conversion of the Pre-Funded Warrants into common stock. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:14 UTC |
Bailey GregoryDirector
|
ConversionCommon Stock | 1,770,805 | $2.25 | $3,984,311.25 |
DisclosureSEC source: 0001329505-26-000007 · wk-form4_1782170066.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,897,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Preferred Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 762,548 shares of Series A Preferred that were converted into 1,755,555 shares of Common Stock and 15,250 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, and the underlying Common Stock shares were issued on June 17, 2026. F2 · balance_after: The share ownership amount has been updated to reflect the correct number of shares beneficially owned by the Reporting Person. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:13 UTC |
WILSON KAREN JDirector
|
GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001267490-26-000008 · wk-form4_1782169998.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F2 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 14:31 UTC |
WILSON KAREN JDirector
|
PurchaseCommon Stock | 5,000 | $1.77 | $8,850.00 |
DisclosureSEC source: 0001267490-26-000006 · wk-form4_1781533906.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 F2 · balance_after: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 14:31 UTC |
WILSON KAREN JDirector
|
PurchaseCommon Stock | 5,100 | $1.75 | $8,899.50 |
DisclosureSEC source: 0001267490-26-000006 · wk-form4_1781533906.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 F1 · balance_after: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 26, 2026 Filed May 27, 2026 19:55 UTC |
LEDGER STEVEN ADirector · Chief Executive Officer
|
GrantCommon Stock | 10,100 | $1.93 | $19,493.00 |
DisclosureSEC source: 0001090206-26-000007 · wk-form4_1779911715.xml · nonDerivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 22, 2026 Filed May 26, 2026 20:26 UTC |
WILSON KAREN JDirector
|
PurchaseCommon Stock | 10,000 | $1.93 | $19,300.00 |
DisclosureSEC source: 0001267490-26-000004 · wk-form4_1779827204.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.90 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 22, 2026 Filed Jun 22, 2026 23:15 UTC |
Venkatesan JayDirector
|
PurchaseCommon Stock | 589 | $1.78 | $1,048.42 |
DisclosureSEC source: 0001413350-26-000004 · wk-form4_1782170099.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 589 F1 · balance_after: The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:37 UTC |
LEDGER STEVEN ADirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 380,825 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001090206-26-000005 · wk-form4_1779838635.xml · derivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,825 Underlying: Common Stock · 380,825 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:44 UTC |
Tenjarla SriniSVP, CMC & Formulation
|
GrantStock Option (right to buy) · Derivative | 85,558 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0002029985-26-000004 · wk-form4_1779839080.xml · derivative · entry 1 Tenjarla Srini · CIK 0002029985 · SVP, CMC & Formulation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,558 Underlying: Common Stock · 85,558 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:35 UTC |
CURHAN GREGORY SChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 123,019 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001263244-26-000002 · wk-form4_1779838527.xml · derivative · entry 1 CURHAN GREGORY S · CIK 0001263244 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,019 Underlying: Common Stock · 123,019 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| May 21, 2026 Filed May 26, 2026 23:33 UTC |
Moreadith RandallChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 85,558 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001301120-26-000021 · wk-form4_1779838407.xml · derivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,558 Underlying: Common Stock · 85,558 shares Expires 2036-05-21 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:26 UTC |
WILSON KAREN JDirector
|
PurchaseCommon Stock | 10,000 | $1.77 | $17,700.00 |
DisclosureSEC source: 0001267490-26-000004 · wk-form4_1779827204.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.79 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 19, 2026 Filed May 22, 2026 20:59 UTC |
Marshall Richard PeterDirector
|
PurchaseCommon Stock | 12,183 | $1.65 | $20,101.95 |
DisclosureSEC source: 0002016188-26-000002 · wk-form4_1779483581.xml · nonDerivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,183 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.59 per share to a high purchase price of $1.73 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| March 31, 2026 Filed Apr 21, 2026 19:45 UTC |
Bailey GregoryDirector
|
GrantCommon Stock | 59,667 | $1.94 | $115,753.98 |
DisclosureSEC source: 0001329505-26-000002 · wk-form4_1776800739.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,910 F1 · shares: These shares of common stock were issued for payment of accrued dividends on the reporting individuals Series A Convertible Preferred Stock issued on April 8, 2025. Read SEC document |
| March 31, 2026 Filed Apr 21, 2026 19:31 UTC |
Venkatesan JayDirector
|
GrantCommon Stock | 7,553 | $1.94 | $14,652.82 |
DisclosureSEC source: 0001413350-26-000002 · wk-form4_1776799907.xml · nonDerivative · entry 1 Venkatesan Jay · CIK 0001413350 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,553 F1 · shares: These shares of common stock were issued for payment of accrued dividends on the reporting individuals A Convertible Preferred Stock issued on April 8, 2025. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $2.86 | $18,567.90 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: 1. The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $3.03. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| March 23, 2026 Filed Mar 24, 2026 23:24 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000018 · wk-form4_1774394662.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274,186 Underlying: Common Stock · 39,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 39,000 | $2.50 | $97,500.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 18:20 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 39,000 | $0.06 | $2,340.00 |
DisclosureSEC source: 0001301120-26-000016 · wk-form4_1774030842.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:20 UTC |
LEDGER STEVEN ADirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 230,100 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001090206-26-000003 · wk-form4_1771334433.xml · derivative · entry 1 LEDGER STEVEN A · CIK 0001090206 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,100 Underlying: Common Stock · 230,100 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:29 UTC |
Tenjarla SriniSVP, CMC & Formulation
|
GrantStock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0002029985-26-000002 · wk-form4_1771334956.xml · derivative · entry 1 Tenjarla Srini · CIK 0002029985 · SVP, CMC & Formulation 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:24 UTC |
GILL SIMBADirector
|
GrantStock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001180763-26-000002 · wk-form4_1771334683.xml · derivative · entry 1 GILL SIMBA · CIK 0001180763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| February 03, 2026 Filed Feb 17, 2026 13:35 UTC |
Moreadith RandallChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001301120-26-000014 · wk-form4_1771335355.xml · derivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: Unless otherwise terminated as provided in the optionee's option agreement, 12/48ths of the shares subject to the option shall vest twelve months after the Vesting Commencement Date, and 1/48th of the shares subject to the option shall vest on the same calendar day of each subsequent month thereafter until the shares subject to the option are fully vested. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,186 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $3.03 | $19,680.05 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.00. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000012 · wk-form4_1770140133.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,686 Underlying: Common Stock · 6,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 6,500 | $3.57 | $23,185.50 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 of Table I is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.59 to $3.55. The reporting person undertakes to provide to Serina Therapeutics, Inc., any security holder of Serina Therapeutis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 17:54 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 6,500 | $0.06 | $390.00 |
DisclosureSEC source: 0001301120-26-000010 · wk-form4_1769709237.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · derivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 326,186 Underlying: Common Stock · 2,500 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,500 | $2.95 | $7,375.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 17:35 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,500 | $0.06 | $150.00 |
DisclosureSEC source: 0001301120-26-000008 · wk-form4_1769189706.xml · nonDerivative · entry 1 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · derivative · entry 6 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 328,686 Underlying: Common Stock · 2,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,000 | $3.00 | $6,000.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 4 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 21, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,000 | $0.06 | $120.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 3 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · derivative · entry 5 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 330,686 Underlying: Common Stock · 2,000 shares Expires 2031-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options are fully vested. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 00:17 UTC |
Moreadith RandallChief Scientific Officer
|
SaleCommon Stock | 2,000 | $3.07 | $6,140.00 |
DisclosureSEC source: 0001301120-26-000006 · wk-form4_1769041031.xml · nonDerivative · entry 2 Moreadith Randall · CIK 0001301120 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.